The agonistic DR5 antibody D-6, a novel candidate for combating C30 cisplatin-resistant ovarian cancer, initiates apoptosis through both cysteine-dependent and independent pathways and may help reduce cisplatin resistance in the C30 cell line (Huang et al., 2014). Here, ACKR2 is linked to ovarian carcinoma.